DiogenX
DiogenX is a preclinical stage biotech company developing first-in-class regenerative biologics for the treatment of type 1 diabetes. The company focuses on discovering therapeutics that modulate pancreatic beta-cells to provide new medical options for diabetic patients globally. Their research is based on work from the Institut de biologie Valrose and aims to restore insulin production.
Biotech
Healthcare
Biopharmaceuticals
Funding summary
- Total raised
- €32.0M
- Funding rounds
- 2
Investors in DiogenX
Investors on record for DiogenX. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like DiogenX?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors